Prostate-cancer mortality at 11 years of follow-up

New England Journal of Medicine

Volumn 366, Issue 11, 2012, Pages 981-990

  Schröder, Fritz H ^a   Hugosson, Jonas ^b   Roobol, Monique J ^a   Tammela, Teuvo L J ^d   Ciatto, Stefano ^b,f,l   Nelen, Vera ^g   Kwiatkowski, Maciej ⁱ   Lujan, Marcos ^j   Lilja, Hans ^l,q   Zappa, Marco ^f   Denis, Louis J ^h   Recker, Franz ⁱ   Páez, Alvaro ^k   Määttänen, Liisa ^m   Bangma, Chris H ^a   Aus, Gunnar ^c   Carlsson, Sigrid ^b,f,l   Villers, Arnauld ⁿ   Rebillard, Xavier ^o   Van Der Kwast, Theodorus ^a   Kujala, Paula M ^d   Blijenberg, Bert G ^a   Stenman, Ulf Hakan ^m   Huber, Andreas ⁱ   Taari, Kimmo ^m   Hakama, Matti ^e,m   Moss, Sue M ^p   De Koning, Harry J ^a   Auvinen, Anssi ^e   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Urologkliniken   (Sweden)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^g Provinciaal Instituut voor Hygiene   (Belgium)

^h Oncology Centre of Antwerp   (Belgium)

ⁱ CANTONAL HOSPITAL AARAU   (Switzerland)

^j HOSPITAL INFANTA CRISTINA   (Spain)

^k HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o Clinique Beausoleil   (France)

^p QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^q LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; CONTROLLED STUDY; EUROPE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SURVIVAL TIME;

EID: 84858212484     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1113135     Document Type: Article

References (29)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med 2009;360:1320-8.
2. Roobol MJ, Schröder FH. The European Randomized study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. BJU Int 2003;92:Suppl 2:1-123.
3. European Randomized Study of Screening for Prostate Cancer: study protocol 1994, admission criteria and minimal data set. Section 4.0: definitions, 4.1 age groups (http://www.erspc.org/publist.php).
4. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
5. de Koning HJ, Blom J, Merkelbach JW, et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003;92:Suppl 2:71-8. (Pubitemid 38091145)
6. de Koning HJ, Hakulinen T, Moss SM, Adolfsson J, Smith PH, Alexander FE. Monitoring the ERSPC trial. BJU Int 2003; 92:Suppl 2:112-4. (Pubitemid 38091153)
7. de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-73. (Pubitemid 34150812)
8. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997;16:1017-29. (Pubitemid 27198989)
9. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612. (Pubitemid 8004970)
10. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994;13:1341-52. (Pubitemid 24236184)
11. Aalen OO. Nonparametric inference for a family of counting processes. Ann Stat 1978;6:701-27.
12. Screening for prostate cancer. Rockville, MD: U.S. Preventive Services Task Force, 2008 (http://www.uspreventive servicestaskforce.org/uspstf/uspsprca. htm).
13. Brett AS, Ablin RJ. Prostate-cancer screening - what the U.S. Preventive Services Task Force left out. N Engl J Med 2011;365:1949-51.
14. McNaughton-Collins MF, Barry MJ. One man at a time - resolving the PSA controversy. N Engl J Med 2011;365:1951-3.
15. Schröder FH. Stratifying risk - the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 2011;365:1953-5.
16. Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 2011;64:1412-7.
17. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011;29:464-7.
18. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78. (Pubitemid 36833878)
19. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4.
20. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
21. Wilt T. Prostate Cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Presented at the annual meeting of the American Urological Association, Washington, DC, May 14-19, 2011. (VA/NCI/AHRQ CSP #407.)
22. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998;317:307-12. (Pubitemid 28353824)
23. Wu GH, Auvinen A, Yen AM, Hakama M, Walter SD, Chen H. A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and overdetection. Biom J 2011 December 23 (Epub ahead of print).
24. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11: 725-32.
25. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010;126:2387-93.
26. Boevee SJ, Venderbos LD, Tammela TL, et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46:3082-9.
27. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9. (Pubitemid 36570054)
28. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003;92:Suppl 2:97-100. (Pubitemid 38091150)
29. Johansson J-E, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291: 2713-9. (Pubitemid 38725420)